Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared a post on LinkedIn:
“Not all “double-hit” lymphomas behave the same.
A new study from MSKCC highlights important biological and clinical differences among high-grade B-cell lymphomas (HGBCL) with MYC rearrangements.
Analyzing 124 patients with advanced-stage HGBCL, investigators found:
- Complete response rate: 44%
- 2-year overall survival: 59.8%
- CNS relapse: 10.1%
Patients treated with dose-adjusted R-EPOCH had better overall survival than those receiving R-CHOP–based regimens.
One of the most notable findings was that MYC/BCL6-rearranged lymphoma demonstrated a particularly aggressive clinical course, with higher rates of CNS relapse and rapid progression after relapse compared with MYC/BCL2-rearranged disease. Molecular profiling also suggested distinct biology, supporting recent classification changes that recognize MYC/BCL6 disease as a separate entity.
Interestingly, contrary to prior observations in DLBCL, patients whose HGBCL transformed from an indolent lymphoma had better survival in this cohort.
These findings reinforce that HGBCL is not a single disease. Understanding the molecular subtype may improve risk stratification, guide frontline treatment decisions, and help identify patients who may benefit from CNS-directed strategies and novel therapies.”
You can also read: Peripheral T-Cell Lymphomas (PTCL): Another Evolving Lymphoma Story
